Kornimate/medical-research-clean huggingface dataset:
effectiveness of different weekly frequency of modified pilates method exercises in the treatment of chronic nonspecific low back pain

Conditions: Low Back Pain

Summary: low back pain is a major cause of disability and absenteeism and the supervised exercise is a recommended treatment by the guidelines and has been cost-effective. currently, the pilates method has shown to be effective in improving pain and disability in patients with chronic low back pain (clbp). however, there is still no evidence about the ideal number of sessions for the treatment and the interval between sessions to achieve better efficacy of this method for these patients. thus, the aim of this study is to investigate the effectiveness of the pilates method with different weekly frequency of sessions in the treatment of patients with nonspecific clbp. investigators will assess 296 patients of both genders, with nonspecific clbp lasting more than three months and aged between 18 and 80 years. participants will be randomly divided into four groups (n = 74 patients per group): control group will receive an educational booklet and no additional exercise, pilates 1 group will receive a program of exercises based on pilates method once a week for six weeks, pilates 2 group will receive the same program of exercises twice a week for six weeks and pilates 3 group will receive the same program of exercises three times a week for six weeks. the outcomes overall disability (roland morris disability questionnaire), specific disability (patient-specific functional scale), kinesiophobia (tampa scale for kinesiophobia), pain intensity (pain numerical rating scale) and global perceived effect (global perceived effect scale) will be assessed by a blinded assessor before, six weeks, six and 12 months after randomization. investigators expect that the largest number of weekly sessions of pilates method may influence the results in all analyzes (short, medium and long term), since there is a relationship between frequency of exercises and effect size of the treatment.


Eligibility criteria:
inclusion criteria: * patients with chronic nonspecific low back pain longer 12 weeks exclusion criteria: * contra indications to physical exercise * serious spinal pathologies (e. g. tumors, fractures and inflammatory diseases) * nerve root compromise * pregnancy * previous surgery on spine * pilates treatment for low back pain in the last three months

Keywords: pilates-based exercises
the safety and effectiveness of 935u83 in hiv-infected patients

Conditions: HIV Infections

Summary: to assess the safety, tolerance, and steady-state pharmacokinetics of multiple oral doses of 935u83 administered to patients with hiv infection. to obtain preliminary evidence of antiretroviral activity of 935u83. to prospectively evaluate the emergence of in vitro drug resistance. to determine the effects of 935u83 dosing on cd4+ cell counts.

patients (10 per dose level) are randomized to receive 1 of 4 doses of 935u83 every 8 hours for 12 weeks. five patients at each dose level must complete 4 weeks of treatment without serious toxicity before subsequent patients are entered at the next higher dose. if lack of antiretroviral effect or unacceptable toxicity is demonstrated at a particular dose level, the dose regimens may be adjusted.

Eligibility criteria:
inclusion criteria concurrent medication: recommended: * pcp prophylaxis for patients whose cd4 counts fall below 200 cells/mm3 or who develop pcp during study participation. allowed: * acute treatment and secondary prophylaxis for tuberculosis, mycobacterium avium intracellulare, toxoplasmosis, histoplasmosis, cryptococcosis, disseminated candidiasis, or cytomegalovirus infection. patients must have: * hiv infection. * cd4 count 200 - 500 cells/mm3. * no history of or current aids-defining indicator disease by cdc criteria. * no antiretroviral therapy within the past 6 months. * consent of parent or guardian if less than 18 years of age. exclusion criteria co-existing condition: patient with the following symptoms or conditions are excluded: * current evidence of chronic hepatitis of any etiology. * seropositivity for hbsag or hepatitis c virus by second generation elisa. concurrent medication: excluded: * cytotoxic chemotherapy. * other antiretroviral drugs. * immunomodulators. * foscarnet. * gm-csf or g-csf. * erythropoietin. concurrent treatment: excluded: * radiation therapy. patients with the following prior conditions are excluded: history of chemical, viral, or alcohol-induced clinical hepatitis within the past 3 years. prior medication: excluded within the past 6 months: * any antiretroviral therapy. * hiv immunotherapeutic vaccine. excluded within the past 4 weeks: * cytotoxic chemotherapy. * immunomodulating agents such as systemic corticosteroids, il-2, alpha interferon, beta interferon, or gamma interferon. prior treatment: excluded within the past 4 weeks: * radiation therapy. current alcohol or illicit drug use that may interfere with study compliance.

Keywords: acquired immunodeficiency syndrome aids-related complex antiviral agents
prescription patterns of oral anticoagulants

Conditions: Atrial Fibrillation

Summary: atrial fibrillation is the major cause of acute ischemic stroke. the risk of stroke was shown to decline by oral anticoagulant therapy. the investigators intended to evaluate appropriate use of anticoagulants in non-valvular af patients.

atrial fibrillation, the most common sustained arrhythmia, is the major cause of acute ischemic stroke. the prognosis of ischemic stroke associated with atrial fibrillation (af) tends to have a worse prognosis for recovery compared with other ischemic stroke subtypes. the risk of stroke was shown to decline to 68% by oral anticoagulant (oac) therapy.the investigators have evaluated appropriate use of anticoagulants in non-valvular af patients. appropriate use of oral anticoagulants was assessed by medication appropriateness index (mai). the mai consists of 10 criteias namely, indication, choice, dosage, modalities and practicability of administration, drug-drug interactions, drug-disease interactions, duplication, duration, and cost-effectiveness. the tenth criteria was not evaluated because of limited data regarding cost-effectiveness of the drugs.

Eligibility criteria:
inclusion criteria: * non valbular af \>18 years exclusion criteria: * not currently receiving anticoagulant
screening of gonococcal and chlamydial infections in the third trimester

Conditions: Gonococcal Infection; Chlamydia Infections

Summary: untreated maternal infection with gonorrhea and/or chlamydia can have serious complications in pregnancy and the neonatal period. in ontario, routine screening for these infections is done in the first trimester of pregnancy, positive cases are treated with antibiotics, and all newborns are given antibiotic eye ointment within 24 hours of birth. recently, the canadian pediatric society recommended stopping universal prophylaxis for newborns, with instead, focus on screening and treatment of these infections in pregnancy. given that these infections can occur at any time in pregnancy, and exposure at delivery provides a significant risk to infants, more information is needed about the rates of infection throughout pregnancy and health-care provider compliance with guidelines to make this change without undue risk. with this information optimal timing of testing can be evaluated.

the primary objective of this study is to retrospectively examine the incidence rates of n. gonorrhoeae (ng) and c. trachomatis (ct) in the first and third trimester for the obstetrical population at st. michael's hospital over the course of six months. secondary objectives include (1) feasibility of instituting third trimester screening for sexually transmitted infections, and (2) assessment of physician compliance with canadian screening and treatment guidelines. this information will help us to deduce the optimal timing of screening for ng and ct in the obstetrical population at st. michael's hospital. it is hypothesized that the incidence rates of both ng and ct infections will be low, but that much can be learned from the positive cases in terms of risk factors and optimal timing of screening. further, the feasibility of screening in the third trimester will offer options for future guidelines.

Eligibility criteria:
inclusion criteria: * all consecutive prenatal patients attending the obstetrical clinic at st. michael's hospital for a six-month period from may 1, 2016 to november 1, 2016, inclusive. exclusion criteria: * none.
pivotal study of the al-sense study protocol

Conditions: Amniotic Fluid Leakage

Summary: the purpose of this study is to demonstrate that the diagnostic absorbent panty liner (al-sense amniotic leak test kit), developed by common sense ltd., can distinguish between wetness sensed by pregnant women that is caused by amniotic fluid leakage and that which is caused by urinary incontinence.


Eligibility criteria:
inclusion criteria: * age 18 to 45 years. * minimum 16 weeks of pregnancy. * willing to sign the informed consent form. * arrived at the obstetric department reporting a feeling of vaginal wetness (undetermined whether this is amniotic fluid leakage or urinary incontinence). exclusion criteria: * experienced intermittent vaginal bleeding between the 2nd and 3rd trimester. * have had sexual relations within the last 12 hours. * unable or unwilling to cooperate with study procedures. * used the al-sense before joining this study. * diagnosed with bacterial vaginosis or trichomonas infection within the last 3 days. * uses vaginal products such as some douching formulas, some antibiotic treatments which reduce lactobacillus population. * uses drugs which reduce estrogen level such as tamoxifen or drugs that dry out the mucous membranes, such as antihistamines * on a diet of alkalizing foods such as alkalive™ green, which may cause elevation of the vaginal ph level.

Keywords: amniotic fluid leakage urinary incontinence pregnancy home test vaginal wetness
china national study of adrenal venous sampling

Conditions: Hyperaldosteronism

Summary: this multicenter study intends to combine retrospective analysis and prospective registry to evaluate the success rate and safety of adrenal venous sampling (avs) via antecubital and femoral approach for patients with primary aldosteronism. the consistency of avs with pathological results and clinical outcomes, the factors affecting the success of avs, and the optimal population for avs will be aslo analyzed in this study.

primary aldosteronism (pa) is one of the most common causes of secondary hypertension, and its most common subtypes are aldosterone-producing adenoma and idiopathic hyperaldosteronism, which account for 95% to 98% of pa. subtype diagnosis is crucial for the treatment of primary aldosteronism, which conducts the appropriate treatment strategy. currently, adrenal venous sampling (avs) serves as the gold standard for subtyping of pa. how to improve the success rate of avs has been a hot topic in the field of primary aldosteronism. this multicenter registry study intends to combine retrospective analysis and prospective registry to evaluate the success rate and safety of avs via antecubital and femoral approach for patients with primary aldosteronism. the consistency of avs with pathological results and clinical outcomes, the factors affecting the success of avs, and the optimal population for avs will be also analyzed in this study.

Eligibility criteria:
inclusion criteria: 1. aged from 18 to 65 with no limits in sex; 2. patients with confirmed primary aldosteronism; 3. patients or their legal representatives sign written informed consent approved by the ethics committee； exclusion criteria: 1. severe comorbidity, including stroke, myocardial infarction, heart failure, severe valvular heart disease, liver cirrhosis, and metastatic tumor within the previous 3 months； 2. an estimated glomerular filtration rate \ 176 μmol/l； 3. patients who refuse adrenalectomy; 4. suspected of having an adrenocortical carcinoma; 5. allergy to contrast agent; 6. pregnant, nursing, or planning to become pregnant

Keywords: adrenal venous sampling hyperaldosteronism antecubital approach femoral approach pathological results
yoga therapy for chronic tension-type headache

Conditions: Chronic Tension-Type Headache

Summary: chronic tension headache represents a considerable social burden in terms of both costs to the health services and also the costs of lost productivity. episodic tension-type headache can be treated with rest and analgesics, while chronic tension-type headache demands a more fundamental treatment. effectiveness of yoga therapy in the management of chronic tension type headache is limited. in this study, yoga therapy was used to explore its effect on chronic tension-type headache.


Eligibility criteria:
inclusion criteria: * meeting the diagnostic criteria of ctth in the international classification of headache disorders, 3rd edition (beta version) (ichd-iii beta); * aged 18-55 years; * having the ability of understanding and completing the headache dairy; * provide written informed consent. exclusion criteria: * no headache during the pervious 3 months; * taking any prophylactic medication during the previous one month; * secondary headache or any systematic cause * having serious conditions of the heart, liver, kidney or other organs; * in pregnancy or lactation, or planning to be pregnant in 6 months; * drug and substance abuse * diagnosed psychiatric condition * taking any other complementary and alternative medicines * practicing yoga of any kind in last three months
eplerenone versus pdt: comparative study by octa

Conditions: Central Serous Chorioretinopathy

Summary: the study aims to analyze the changes in octa parameters and in choroidal thickness in patients affected by central serous chorioretinopathy treated by oral eplerenone and half-fluence photodynamic therapy.

central serous chorioretinopathy (csc) is a chorioretinal disease characterized by serous detachment due to the dilatation and hyperpermeability of choroidal vessels resulting in the accumulation of serous fluid between the neurosensory retina and the retinal pigment epithelium. several studies reported the efficacy of half-fluence photodynamic therapy (pdt) and oral eplerenone in the csc treatment inducing a reduction of the choroidal hyperpermeability and remodeling the choroidal vascularization. this retrospective study aims to perform a quantitative analysis of retinal and cc vessel density by octa at baseline, 3 and 6 months in patients underwent pdt and patients underwent eplerenone.

Eligibility criteria:
inclusion criteria: * age older than 30 years * diagnosis of central serous chorioretinopathy * treatment-naïve with half-fluence photodynamic therapy or oral eplerenone * absence of vitreoretinal and vascular retinal diseases exclusion criteria: * age younger than 30 years * absence of diagnosis of central serous chorioretinopathy * previous treatment with half-fluence photodynamic therapy or oral eplerenone * presence of concomitant vitreoretinal and vascular retinal diseases
a study using rapid acting intramuscular olanzapine in agitated patients with schizophrenia

Conditions: Schizophrenia

Summary: to investigate dose-response of rapid acting intramuscular olanzapine in agitated patients with schizophrenia


Eligibility criteria:
inclusion criteria: * patients must have schizophrenia that meets disease diagnostic criteria in dsm-iv-tr * patients must be inpatients during the study * patients must have a minimum total score of no less than 14 on the five items of the panss-ec and at least one individual item score of no less than 4 using the 1-7 scoring system prior to the first injection of study drug exclusion criteria: * patients who have a known history of diabetes mellitus. * patients who have received treatment with antipsychotics or other prohibited concomitant medicines within 2 hours prior to the first im study drug administration * patients who have had treatment with benzodiazepines within 4 hours prior to first im study drug administration.
interactive care plan for the monitoring of symptoms and recovery in patients with stage 0-iii breast cancer

Conditions: Anatomic Stage 0 Breast Cancer AJCC v8; Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8

Summary: this phase i trial evaluates how well a mobile device-based breast cancer survivorship interactive care plan works in monitoring symptoms and recovery in patients with stage 0-iii breast cancer. the interactive care plan provides patients with individualized, 'just in time' education materials to promote self-management for those reporting difficult to control symptoms, as well as escalations to contact their care team for signs or symptoms concerning for cancer coming back (recurrence). the interactive care plan may help alleviate the symptoms of fatigue, insomnia, hot flashes, and sexual dysfunction; increase physical activity level and improve quality of life in patients with breast cancer.

primary objectives: i. to evaluate the feasibility and usability of the breast cancer (bc) survivorship interactive care plan (icp) as designed. ii. to determine the behavioral, toxicity symptom burden and quality of life (qol) changes in patients engaged with the icp. iii. to assess clinical workflow impact by the introduction of the icp in the bc survivor practice. outline: patients complete surveys for 4 common symptoms: fatigue, hot flashes, insomnia, and sexual dysfunction and receive educational material via mobile application (app) to help with bothersome symptoms. patients also complete questionnaires.

Eligibility criteria:
inclusion criteria: * recently diagnosed and treated for breast cancer -- having a biopsy-proven, stage 0-iii breast cancer and are within 12 months of completion of loco-regional breast cancer treatment and (as indicated) neoadjuvant and/or adjuvant chemotherapy. ongoing treatment with adjuvant endocrine, bisphosphonate, and single-agent, her2-directed therapy during the study period is allowed * willing to install an application (app) on personal smart device exclusion criteria: * unwilling to return to mayo clinic for routine follow-up visits * unwilling to use the mayo clinic mobile app * unable to provide consent * unable to speak or read english * unable to participate in mild activity
the impact of ureteral stents on peristalsis

Conditions: Kidney Stones; Tumor; Hydronephrosis

Summary: the purpose of the study is to investigate the impact of ureteral stents on the functioning of ureteral peristalsis (normal contractions in the ureteral organ muscle).

ureteral stents are commonly used in the field of urology to maintain urinary drainage and are inserted into ureters of patients who suffer from kidney stones, urinary tract infections or cancer. usually the muscle cells of the ureter contract in a coordinated fashion (peristalsis) in order to provide urinary flow from the kidney into the bladder. by inserting a stent these contractions are disrupted, eventually resulting in a loss of peristalsis. this phenomena is accompanied by swelling of the kidney and pain, which are well-known negative side effects of stents. to avoid stent-related morbidity and improve patients care this issue needs to be investigated further. a first step is to analyse the impact of stents on peristalsis and to possibly bring these results into context with hypothesised molecular mechanisms involved in peristalsis.

Eligibility criteria:
inclusion criteria: 1. stone disease 2. localized tumor disease 3. hydronephrosis of unknown ethiology 4. patients who receive a prophylactic stent before a planned operation. exclusion criteria: 1. patients being septic and in a life-threatening condition before or after stent-insertion 2. patients with tumors in a progressive state that affect the retroperitoneum (contralateral ureter might be affected and can not serve as a control for the stented side) 3. patients with morbus ormond (same reason as above) 4. patients requiring ureteral stents bilaterally (same reason as above) 5. long-term stented patients will be excluded as we are interested in evaluating the onset of changes in peristalsis rate which are expected to be most significant in an acute setting. 6. patients with preexisting abnormalities/pathologies of the urinary tract e.g. reflux disease, megaureter or bladder dysfunctions as these will likely affect our results 7. non english-speaking patients will be excluded as they will not be able to understand the letter of consents. exclusion criteria for control group: 1. known preexisting pathology in the urinary tract (see above) 2. volunteers who underwent previous surgical procedures on kidney, ureter or bladder within the past 5 years as this may change the starting position of our study 3. patients currently taking an α-blocker (alfuzosin, terazosin, doxazosin, tamsulosin, prazosin) because these medications are known to affect peristalsis 4. patients currently taking calcium channel blocker (verapamil, diltiazem, nifedipine, nicardipine, bepridil, mibefradil) because these medications are known to affect peristalsis

Keywords: peristalsis, kidney stones, hydronephrosis, ureteral stent
weight maintenance through physical activity and social support in rural middle-aged women

Conditions: Body Weight Changes

Summary: the purpose of this study is to compare an technology-based weight maintenance intervention using action plans, videos discussion boards and health behavior tracking (weight, calories in and out, pedometer steps) with a technology-based standard advice group to facilitate health management, resourcefulness and health status for rural middle-aged women.

the purpose of this research project is to evaluate the influence of a theory-based intervention using the health effects of life transitions for women model to promote maintenance of initial weight loss. the intervention will be designed to promote physical activity to prevent weight regain among an underserved and vulnerable population of rural, mid-life women. the intervention delivered through action plans, videos, discussion boards and health behavior tracking (weight, calories in and out, pedometer steps) to facilitate health management, resourcefulness and health status will be compared with the standard advice group who receives newsletters and health behavior tracking (weight) to initiate, increase, or sustain physical activity for weight maintenance.

Eligibility criteria:
inclusion criteria: women: * aged 40-64 years; * reported intentional weight loss of 5-10% of initial body weight within previous 6 months; * residing in a rural county (population \< 50,000 residents) or rural community (population less than 2,500) within driving distance of a unmc college of nursing campus; * ability to communicate in english (verbal and written); * ambulatory and can walk at least one block without the use of an assistive device, such as a cane, walker, or wheelchair; * have access to the internet and current email account; and * answer 'no' to all questions on the physical activity readiness questionnaire (par-q) or obtain clearance from their physician to become more active. exclusion criteria: * instructed by a physician not to exercise; * presence of chest pain, shortness of breath, or feelings of light-headedness upon exertion.